Akero Retained Earnings from 2010 to 2024

AKRO Stock  USD 31.23  0.41  1.33%   
Akero Therapeutics Retained Earnings yearly trend continues to be very stable with very little volatility. Retained Earnings are likely to grow to about -545.4 M this year. Retained Earnings is the cumulative amount of net income that Akero Therapeutics retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals
 
Retained Earnings  
First Reported
2017-12-31
Previous Quarter
-627.4 M
Current Value
-683.4 M
Quarterly Volatility
193.9 M
 
Covid
Check Akero Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akero Therapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 3.3 M or Selling General Administrative of 16.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.41. Akero financial statements analysis is a perfect complement when working with Akero Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Akero Therapeutics Correlation against competitors.
To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.

Latest Akero Therapeutics' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Akero Therapeutics over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Akero Therapeutics' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Akero Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (574.1 M)10 Years Trend
Slightly volatile
   Retained Earnings   
       Timeline  

Akero Retained Earnings Regression Statistics

Arithmetic Mean(154,336,813)
Coefficient Of Variation(135.57)
Mean Deviation171,996,151
Median(4,564,000)
Standard Deviation209,240,484
Sample Variance43781.6T
Range569.5M
R-Value(0.88)
Mean Square Error11049.1T
R-Squared0.77
Significance0.00002
Slope(40,940,034)
Total Sum of Squares612942.1T

Akero Retained Earnings History

2024-545.4 M
2023-574.1 M
2022-422.3 M
2021-310.3 M
2020-209.5 M
2019-130.3 M
2018-86.6 M

Other Fundumenentals of Akero Therapeutics

Akero Therapeutics Retained Earnings component correlations

About Akero Therapeutics Financial Statements

Akero Therapeutics investors utilize fundamental indicators, such as Retained Earnings, to predict how Akero Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Retained Earnings-574.1 M-545.4 M
Retained Earnings Total Equity-380.1 M-361.1 M

Pair Trading with Akero Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Akero Stock

  0.64ERNA Eterna TherapeuticsPairCorr
  0.63VALN Valneva SE ADRPairCorr
  0.63MBIO Mustang BioPairCorr
  0.57MOLN Molecular PartnersPairCorr
  0.56PTN Palatin TechnologiesPairCorr
The ability to find closely correlated positions to Akero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akero Therapeutics to buy it.
The correlation of Akero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Akero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akero Therapeutics Stock:
Check out the analysis of Akero Therapeutics Correlation against competitors.
To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.44)
Return On Assets
(0.19)
Return On Equity
(0.29)
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.